Drug Profile
Research programme: antifungals - Schering-Plough
Alternative Names: SCH-725680Latest Information Update: 17 Nov 2009
Price :
$50
*
At a glance
- Originator Oscient Pharmaceuticals; Schering-Plough
- Developer Schering-Plough
- Class Benzopyrans
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 18 Jun 2007 Preclinical development is ongoing
- 17 May 2006 This programme is still in active development
- 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals